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Background: Anthrax is caused by the bacterium Bacillus anthracis and is regarded as one of the most prominent
bioterrorism threats. Anthrax toxicity is induced by the tripartite toxin complex, composed of the receptor-binding
anthrax protective antigen and the two enzymatic subunits, lethal factor and edema factor. Recombinant
lactobacilli have previously been used to deliver antibody fragments directed against surface epitopes of a variety
of pathogens, including Streptococcus mutans, Porphyromonas gingivalis, and rotavirus. Here, we addressed whether
or not anthrax toxins could be targeted and neutralised in the gastrointestinal tract by lactobacilli producing
recombinant antibody fragments as a model system for toxin neutralisation in the gastrointestinal lumen.
Results: The neutralising anti-PA scFv, 1H, was expressed in L. paracasei as a secreted protein, a cell wall-anchored
protein or both secreted and wall-anchored protein. Cell wall display on lactobacilli and PA binding of the
anchored constructs was confirmed by flow cytometry analysis. Binding of secreted or attached scFv produced by
lactobacilli to PA were verified by ELISA. Both construct were able to protect macrophages in an in vitro
cytotoxicity assay. Finally, lactobacilli producing the cell wall attached scFv were able to neutralise the activity of
anthrax edema toxin in the GI tract of mice, in vivo.
Conclusion: We have developed lactobacilli expressing a neutralising scFv fragment against the PA antigen of the
anthrax toxin, which can provide protection against anthrax toxins both in vitro and in vivo. Utilising engineered
lactobacilli therapeutically for neutralising toxins in the gastrointestinal tract can potential be expanded to provide
protection against a range of additional gastrointestinal pathogens. The ability of lactobacilli to colonise the
gastrointestinal tract may allow the system to be used both prophylactically and therapeutically.
Background
Spores of Bacillus anthracis have for long been regarded
as one of the most powerful bioterrorism threats due to
their stability and high lethality [1]. The spores can be
easily produced and stockpiled in large quantities, using
simple microbial techniques by people having access to
av i r u l e n ts t r a i na n di n c e n t i v et ob ee x p o s e dt ot h er i s k
connected with its propagation and handling. Previous
deliberate spread of anthrax spores as agent of biowar-
fare has been as aerosol. However, they could also be
disseminated through the food or water supply for tar-
geting of the gastrointestinal tract.
Anthrax infections fall into three different categories,
reflecting the route of entry; inhalational, gastrointestinal
or cutaneous in order of severity of the infection. With
regard to bioterrorism, the most realistic mode of mass
exposure includes inhalational or gastrointestinal infec-
tions. Conceptually, the idea of targeting the food supply
is not new [2] and a few records of planned use of
anthrax spores for deliberately targeting the oral route
exist [3,4]. However, relatively little is known about the
pathophysiology of gastrointestinal anthrax, despite its
prevalence in ruminant livestock. Initial infection is
established in the Peyer’’s Patches throughout the small
intestine, eventually leading to systemic infection by
spreading to the draining jejunal lymph nodes, the spleen
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anthracis preferentially occurs after abrasions in the
mucosa but can also occur in the absence of damage in
which case infection propagation is slower [5]. Natural
occurrence of human gastrointestinal anthrax in the wes-
tern world is rare due to the high standard of the food
supply chain but is more common than inhalational
anthrax in the developing world [6].
The pathogenesis of B. anthracis is due to the product of
three plasmid encoded (pXO1) toxicity genes; pagA (PA),
lef (LF) and cya (EF) expressing a tripartite protein com-
plex, causing the lethal symptoms associated with anthrax.
The protective antigen (PA) combines with the lethal fac-
tor (LF) and edema factor (EF) to form the lethal toxin
(LT) and edema toxin (ET) respectively [7]. PA is the com-
ponent affording binding to either of two receptors, the
tumor endothelial marker 8 (TEM8) and the capillary
morphogenesis 2 (CMG2) [8]. The receptor bound PA is
proteolytically activated facilitating oligomerization of PA
into a heptameric prepore structure, forming the binding
sites for LF and EF. The complete toxin complex is endo-
cytosed and, upon acidification of the early endosome, the
prepore undergoes conformational change whereby LF
and EF are translocated into the cytosol (for review see
[9]). LF is a metalloprotease cleaving MAPK (mitogen-
activated protein kinase) kinases [10], inactivating MAPK
signaling pathways and inducing an atypical vascular col-
lapse in mice [11]. EF is a calmodulin-dependent adenylate
cyclase which increases cyclic AMP levels in cells and
induces extensive intestinal fluid accumulation and
hemorrhaging lesions [12,13]. Both active and passive vac-
cination strategies against anthrax have previously been
attempted and directed primarily towards inactivation of
the toxin components, where PA is the dominant immu-
nogen, and several neutralising antibodies binding to epi-
topes blocking the binding to its receptors have previously
been developed [14,15].
Anthrax Vaccine Adsorbed (AVA) is at present the only
vaccine licensed for use in the United States for prophylac-
tic treatment against anthrax. However, the vaccine
requires multiple injections over 12-18 months in order to
be effective [16] and due to its cost and side effects, thera-
peutic treatment is currently considered more cost effec-
tive [17,18]. Therapeutic treatment for anthrax infection is
based on antibiotic use, post exposure vaccination and
anti-toxin antibodies, with a combinatorial approach of
rapid post exposure vaccination combined with antibiotics
treatment being the most promising [19]. Faced with the
possibility of anthrax strains being engineered for resis-
tance to current antibiotics, the need for alternative treat-
ments grow.
Lactobacilli are Gram-positive bacteria constituting part
of the normal oro-gastrointestinal flora [20] and generally
regarded as safe (GRAS) for human consumption. Their
ability to colonise and thrive in the gastrointestinal tract
has directed attention to their potential use for therapeutic
and prophylactic delivery of biomolecules [21]. Engineered
lactobacilli have previously been used to deliver antibody
fragments targeting both viral and bacterial infections
[22,23]. ScFvs, while retaining the specificity of the mono-
clonal antibody from which they are derived, has a simpler
structure, allowing production in bacterial expression sys-
tems. Several anthrax toxin neutralising scFvs have been
derived from neutralising monoclonal antibodies or by
panning of scFv libraries. The anti-anthrax PA scFv 1H is
derived from the 14B7 monoclonal antibody through
molecular evolution, yielding a highly stable scFv with
increased binding affinity [24].
We have developed several recombinant lactobacilli
expressing a single-chain antibody fragment (1H scFv)
against the PA toxin, and tested their ability to provide
passive immunity against anthrax toxin in the gastroin-
testinal tract.
Results and discussion
Construction of anti-PA expressing recombinant
Lactobacillus
A series of anti-PA neutralising scFvs have previously been
generated through random mutagenesis of the monoclonal
antibody 14B7 [24]. The 1H scFv, had a Kd of 0.25 nM,
nine fold lower than the parent monoclonal antibody and
provided protection both in vitro and in vivo [24]. To eval-
uate the therapeutic potential of Lactobacillus expressing a
scFv against anthrax toxin, a series of expression cassettes
was constructed with the 1H scFv encoding gene placed
under the control of the apf promoter and fused to the apf
signal peptide at the N-terminal and with a C-terminal E-
tag for detection (Figure 1). Variations in the C-terminal
parts of the plasmids gives rise to three different methods
of production of the scFv. In pAF100-1HscFv, a stop
codon just terminal of the E-tag leaves the scFv secreted
into the media (referred to as a secreted construct),
pAF900-1HscFv has the C-terminal E-tag fused to the
prtP anchoring domain leading the scFv to be covalently
bound and displayed on the cell wall upon secretion from
the cell (referred to as an anchored construct), and lastly,
pAF400-1HscFv, where the E-tag is fused to the anchoring
domain of the apf gene which attaches the scFv non-cova-
lently to the cell wall upon secretion, (referred to as an
attached construct).
Expression and correct localisation of the three con-
structs upon transformation into Lactobacillus paracasei
was verified by Western blot analysis of the supernatant
and cell fractions of cultures grown in MRS (Figure 2A).
The scFv expressed by both the secreted (KKA308) and
anchored constructs (KKA307) were found primarily in
the expected fraction, the supernatant for KKA308 and
the cell fraction for KKA307. Some scFv were found in
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anchored construct, which is likely to be due either to
saturation of anchoring sites or inefficient anchoring of
the scFv. For lactobacilli expressing the attached con-
struct, KKA317, the scFv was found to be bound to the
cell wall but also secreted into the media in significant
amounts. This is probably due to the weaker nature of
the non-covalent binding to the cell wall of the APF
binding domain. The total scFv production for the lacto-
bacilli expressing the attached construct was 2-3 fold
higher, relative to the two other constructs, despite being
expressed from the same promoter. We have previously
observed this effect for scFv fusions to the APF anchoring
domain [25] suggesting that the fusion could be benefi-
cial for the secretion or stability of the scFv fragments in
the supernatant.
The three expression constructs provide a choice for
the mechanism of neutralisation 1; anchored and
attached scFv constructs immobilising PA on the cell
wall of the lactobacilli and clearing of bound PA from
the intestinal tract by gastric emptying 2; secreted scFv
expression as seen both using the secreted construct
Figure 1 Plasmid constructs for expression of the 1H scFv in lactobacilli based on the expression cassette from the apf gene from
Lactobacillus crispatus M247. Variations in the anchoring domain and placement of the translational stop codon gives respectively secreted,
cell wall anchored or attached production of the scFv. The APF promoter (P), APF signal peptide (blue), APF anchoring domain (light blue),
translational stop codon (arrowhead), 1H scFv (white), prtP anchor (yellow), E-tag (orange) and transcriptional terminator (lollipop) are indicated.
Figure 2 (A) Detection of the scFv expressed by recombinant L. paracasei by immunoblotting. Cell extract (c) of cell wall anchored strain
(KKA307), secreted strain (KKA308) and attached strain (KKA317). Culture supernatant (s) from cell wall anchored strain (KKA307), secreted strain
(KKA308) and attached strain (KKA317). The expected size of L. paracasei produced scFvs was 57.1, 29.2 and 42.2 KDa for the anchored, secreted
and attached constructs respectively. (B) Binding and quantification of anti-PA scFv secreted into the growth media of the recombinant
lactobacilli as measured by ELISA, with 1H scFv purified from E. coli as a reference (average of 4 experiments).
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tion of the scFv are non-cell wall attached, leading to
diffusion of the neutralising scFvs in the gastrointestinal
lumen with subsequent binding and inactivation of PA.
Binding activity of 1H scFv
Binding activity of the scFv from the culture superna-
tants from lactobacilli transformed with the secreted
and attached constructs, was analysed by ELISA. ScFvs
from both strains bound to PA coated microtiter plates
(Figure 2B). Six and a half ng/ml (0.224 nM) and nine
ng/ml (0.216 nM) was produced by the lactobacilli
expressing the secreted and attached construct respec-
tively, when quantified using a purified His tagged 1H
scFv produced in E. coli as a positive control.
Presence of the 1H scFv on the cell wall in the lactoba-
cilli transformed with the anchored (KKA307) or attached
(KKA317) construct was tested by flow cytometry (using
staining with a mouse anti-E-tag antibody together with a
FITC conjugated rabbit anti-mouse immunoglobulin anti-
body) (Figure 3A). For the anchored construct (KKA307),
a strong positive signal confirmed the surface location of
the scFv. Bacteria transformed with the attached construct
(KKA317) did not stain, indicating that either the scFv is
not displayed on the surface or that the E-tag is embedded
in the membrane due to its close proximity to the anchor-
ing domain and thus not accessible to the anti-E-tag
antibody.
Using PA conjugated florescent beads, a strong binding
to the KKA307 strain (displaying 1H scFv cell wall
anchored), but not strain KKA317 displaying 1H scFv
attached was observed (Figure 3B). The lack of binding
observed with the lactobacilli expressing the attached con-
struct might arise due to that the scFv are not protruding
far enough from the cell wall to afford effective binding.
We have recently shown that close proximity of the scFv
attached with the APF anchoring domain may inhibit the
binding activity of a cell wall anchored scFv [25]. Insertion
of an spacer increasing the length of the anchoring
domain could potentially resolve this as it has previously
been shown by us to improve binding of cell wall display
of antibody fragments [23].
In vitro protection
The ability of the Lactobacillus produced anti-PA scFvs
to protect against the toxin in vitro was assessed using
the J774 MF cell line by exposing it to a lethal dose LT.
Two fold serial dilutions of the 1H scFv, purified from
the supernatant from the KKA308 (secreting) and
KKA317 (attached) strains, were pre-mixed with the
toxin complex (PA and LF) before challenge. A dose of
1.25 μg/ml of secreted scFv afforded complete protection,
corresponding to a molar ratio of 3.5:1 of 1H scFv (29.2
KDa) to PA (83.3 KDa) (Figure 4B). The scFv from the
lactobacilli transformed with the attached construct (42.2
KDa), afforded nearly full protection at a dose of 2.5 μg/
ml and full protection was conferred at 5 μg/ml, translat-
ing to a molar ratio of 5:1 and 10:1 respectively. 1H scFv
produced and purified from E. coli were also tested and
showed protection at corresponding doses (data not
shown) indicating that the binding affinity of the 1H scFv
fragment is maintained when utilising the Lactobacillus
based expression system.
In vivo protection
To test the prophylactic effect of recombinant lactobacilli
expressing the 1H scFv we developed a mouse model of
oral challenge with Bacillus anthracis edema toxin (ET).
ET was previously shown to cause massive fluid retention
and swelling (edema) and intravenous injection shown to
induce intestinal intralumenal fluid accumulation [13]. In
our model of oral ET challenge a dose of 50 to 100 μgE T
causes a significant fluid accumulation in the small and
large intestine 16 hours post oral exposure leading to a
10-15% increase in total intestinal weight (Table 1). To
mimic a stable colonisation achievable with good colonis-
ing bacterial strains the recombinant lactobacilli were
given both 4 hours before and simultaneous with the toxin
challenge. Mice receiving Lactobacillus expressing the
attached construct (KKA317) and no ET were used as
negative controls and had a median relative intestinal
weight of 9.48% of the total body weight (Table 2). The
groups receiving either toxin only or the non-protective
L. paracasei pAF400 expressing attached a scFv against an
irrelevant antigen (SAI/II from S. mutans) together with
ET, had median relative intestinal weights of 10.67% and
10.99%, giving an increase in the median relative intestinal
weight of 12.6% and 15.9% respectively (P< 0.05 for both).
For the group treated with Lactobacillus expressing the
1H scFv in an attached form (KKA317), the median rela-
tive intestinal weight was 9.53% upon challenge with ET,
i.e. in the same range as the negative control and signifi-
cantly lower compared to mice receiving ET only (P<
0.05), indicating a blocking of the uptake of ET in the
intestine. Mice treated with Lactobacillus expressing 1H
scFv either in a secreted or anchored form together with
ET, did not show any significant difference when com-
pared to the ET only group (data not shown).
The reason why, in contrast to the attached construct,
the secreted or anchored constructs failed to provide pro-
tection, remain to be elucidated. One explanation might
be the dual function of the attached construct where the
scFv is both cell wall displayed and secreted into the
supernatant. The secreted part of the 1H scFv produced
by the attached construct would have an unbound cell
wall attaching domain, allowing it to re-attach to the cell
wall of lactobacilli after binding to PA. This could theore-
tically provide a therapeutic advantage as the lactobacilli
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reservoir for the attached 1H scFv, mopping up PA and
immobilising it on the bacteria.
To examine if the attached 1H scFv could re-attach to
the cell wall of lactobacilli we therefore grew a non-
expressing strain of L. paracasei (KKA101) in media with
and without the attached 1H scFv. Western blot analysis
of the cell pellet of the cultures showed a clear re-attach-
ment of the 1H scFv on the cell wall of the non-expres-
sing strain (KKA101) when grown in media containing
the scFv (Figure 5). Homologous binding domains are
also found in other Gram-positive bacteria [26,27] but
further studies would be needed to determine if re-
attachment also occur on other bacteria and if this is a
parameter for neutralisation with the attached construct.
However since only one of three constructs was suc-
cessful in providing neutralisation in vivo certain issues
still needs to be addressed for therapeutic engineering of
lactobacilli for antibody expression. The length of the
anchoring domain and polarity of the scFv might influ-
ence the extension of the scFv from the bacterial cell wall
for and thereby affect binding. Stability of secreted scFvs
Figure 3 Flow cytometry analysis of lactobacilli surface displayed scFvs. (A) Visualisation of the production and display of the 1H scFv on
the surface of recombinant L. paracasei presenting the scFv anchored (KKA307) or attached (KKA317) (wt L. paracasei was as a negative control).
ScFvs were visualised by detection of the E-tag fused to the scFv using a mouse anti-E-tag antibody in conjunction with a FITC conjugated
rabbit anti-mouse immunoglobulin antibody. (B) Binding of recombinant L. paracasei through surface displayed 1H scFv to PA coated fluorescent
beads. The display of scFv on surface visualised through binding of mouse anti-E-tag antibody and FITC conjugated rabbit anti-mouse
immunoglobulin antibody. 1,1 quarter: unlabeled L. paracasei, 2,1 quarter: scFv displaying L. paracasei, 1,2 quarter: PA conjugated fluorescent
beads and 2,2 quarter: PA conjugated beads bound by L. paracasei.
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neutralisation and engineering of the scFvs for improved
stability in the gastrointestinal lumen would likely
improve the therapeutic effect [28,29].
The strategy of using lactobacilli for delivery of protective
antibody fragments relies on their ability to thrive and
colonise in the gastrointestinal tract. In the described study
a engineered laboratory strain of L. paracasei were used as
a proof of concept for mediation of in situ neutralisation in
the gastrointestinal tract. For efficient continuous delivery
of antibody fragments a Lactobacillus strain characterised
for long-term colonisation in the host should be selected.
Figure 4 In vitro neutralisation of anthrax LT by purified Lactobacillus produced scFv.( A )In vitro neutralisation by L. paracasei produced scFvs of
anthrax LT in a macrophage toxicity assay (cell viability) visualised by staining with MTT. Comparison of neutralising capabilities of the secreted 1H scFv
produced by KKA308 and the attached 1H scFv produced by KKA317 with the corresponding secreted and attached SAI/II as negative controls. (B)
Quantification of in vitro neutralisation by colorimetric measurement of the break down of MTT into dark blue MTT-formazan.
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cessfully used as a delivery system for oral vaccination
with recombinant PA fused to a dendritic cell targeting
peptide, giving a protective response four weeks after first
oral dose [30]. Though effective, induction of a protective
immune response might be too slow to provide protection
in the case of an imminent risk of exposure. For effective
protection a dual strategy of both passive immunity and
oral vaccination could therefore be advantageous provid-
ing both rapid protection and protective immunity.
The use of toxin neutralising antibody fragments in the
gastrointestinal tract can potentially be used as treatment
against other pathogens like Clostridium difficile, Vibrio
cholera and E.coli O157:H. Recently a neutralising single
domain antibody fragment (VHH) against Clostridium dif-
ficile toxin A was developed [31] illustrating this approach.
We have previously shown that VHH can be produced at
high levels using the described expression system and in
addition have advantages over scFvs for expression in lac-
tobacilli [25], so as more VHH are being developed their
use expressed from engineered lactobacilli for therapies in
the gastrointestinal tract will likely increase.
Conclusion
Our results demonstrate a possibility of employing a
recombinant approach for neutralisation of bacterial tox-
ins in the gastrointestinal tract as illustrated here, targeting
anthrax toxins, using genetically engineered Lactobacillus.
I nt h ep r e s e n ts t u d yw eh a v es h o w nt h a tah i g ha f f i n i t y
anti-PA scFv can be expressed both cell wall anchored and
secreted by lactobacilli and retain its binding affinity.
In vivo neutralisation was achieved in a mouse model of
oral toxin challenge with engineered lactobacilli expressing
the neutralising scFv with an APF anchoring domain.
Using recombinant Lactobacillus for induction of passive
immunity in the gastrointestinal tract as described in this
study provides a possibility for a continuous delivery of
the antibody in situ that can be used both therapeutically
and prophylactically. The approach can also be extended
to targeting of a range of toxins produced by a variety of
gastrointestinal pathogens.
Materials and methods
Bacterial strains, plasmids and growth conditions
E. coli DH5a (Invitrogen, Carlsbad, CA) was grown in LB
media at 37°C with 220 rpm orbital shaking or on LB-agar
plates at 37°C. Lactobacilli were grown in lactobacilli MRS
broth (Difco, Sparks, MD) at 37°C without agitation or
anaerobically on MRS-agar plates (BD - GazPak EZ,
Sparks, MD). Antibiotics were added at the following con-
centrations when indicated: ampicilin (100 μg/ml) and ery-
thromycin (300 μg/ml E. coli and 5 μg/ml lactobacilli).
Construction of recombinant Lactobacillus and E. coli
strains
The 1H scFv was amplified from the pMoPac16 vector
containing the 1H scFv [24] using the primers; anthrx1H-
Fw: 5’’-CCGGCCATGGATGATATTCAGATGACACA-
GACTAC-3’’ and anthrx1H-Rv: 5’’-GCACCTGCGGCC
GCCGAGGAGACGGTGACTGAG-3’’.T h eP C Rf r a g -
ment was cloned into pGEM
®-T easy vector (Promega,
Madison, WI) and DNA sequence verified by sequencing.
Table 1 Dose study of oral challenge with edema toxin
Oral dosage n Median Minimum/maximum Relative median weight
a (%) P value
No toxin 12 9.49 7.06/10.43 —— ———
10 μg ET 5 9.51 7.12/10.49 0.21 NS
25 μg ET 6 10.24 8.27/10.94 7.90 NS
50 μg ET 6 10.71 10.39/11.44 12.86 < 0.05
b
100 μg ET 5 10.69 10.46/11.65 11.87 < 0.05
b
Median (minimum and maximum) relative intestinal weight in percent total body weight upon challenge with increasing doses of edema toxin.
a The difference
in median of relative intestinal weight between experimental group and mice receiving no toxin in percent.
b Represents a statistically significant difference of
P< 0.05 compared with mice receiving no toxin using the Mann-Whitney U-test.
Table 2 Mouse model of oral challenge by edema toxin
Oral dosage n Median Minimum/
maximum
Relative median
weight
a (%)
P value compared to
KKA317 only
P value compared to ET
only
ET only 4 10.67 10.48/11.53 12.55 < 0.05
b ——
KKA317 only (negative
control)
5 9.48 7.13/10.51 —— ——— < 0.05
c
KKA317 + ET 8 9.53 7.25/10.89 0.53 NS < 0.05
c
L. paracasei pAF400 + ET 3 10.99 9.99/11.05 15.93 < 0.05
b NS
Median (minimum and maximum) relative intestinal weight in percent total body weight upon challenge with either ET, recombinant Lactobacillus or both.
a The
difference in median of relative intestinal weight between group and negative control KKA317 in percent.
b Represents a statistically significant difference of P<
0.05 compared with mice only receiving KKA317 using the Mann-Whitney U-test.
c Represents a statistically significance of P< 0.05 compared with mice receiving
only ET toxin using the Mann-Whitney U-test.
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restriction enzymes (Promega) and ligated into the NcoI/
NotId i g e s t e dLactobacillus expression vectors, pAF100,
pAF400 and pAF900 [25] giving plasmids pAF100-
1HscFv, pAF400-1HscFv and pAF900-1HscFv for secreted,
attached and anchored expression respectively. The
expression plasmids were transformed into L. paracasei
(previously known as L. casei or L. zeae ATCC 393
pLZ15
- [32]) by electroporation as previously described
[23,33], generating the Lactobacillus strains KKA307,
KKA308 and KKA317 expressing the 1H scFv anchored,
secreted and attached respectively. A Lactobacillus strain,
KKA101, harboring a non-expressing version of the plas-
mid was constructed by transforming L. paracasei with
the empty pIAV7 plasmid [34]. The Lactobacillus strain
L. paracasei pAF400, expressing an attached scFv against
an irrelevant antigen (SAI/II from S. mutans) has been
described previously [25].
An E. coli strain for periplasmic expression of the 1H
scFv was constructed by amplifying the scFv fused to the
E-tag from pAF900-1HscFv with primers anthrx1H-
pOPE-Fw: CGGCCATGGCGGATATTCAGATGACA-
CAGACTAC and pOPE-Etag-Rv: CCGTATCCGGACC
CGCTGGAACCGCGTCATCATCACCATCATCAT-
TAATCTAGAGCC. The PCR fragment was restriction
digested with NcoIa n dBglII (Promega) and cloned into
the NcoI/BglII digested plasmid pOPE101-215(yol) [35]
generating pOPE101-1HscFv(E-tag). The plasmid was
transformed into E. coli XL1-Blue competent cells (Agi-
lent, Santa Clara, CA) by electroporation generating the
Figure 5 Re-attachment of 1H scFv to the cell wall of L. paracasei detected by immunoblotting. Pellet fraction of attached strain (KKA317)
and (KKA101) grown in conditioned media containing 1H scFv (lane 1 and 3 respectively). Pellet fraction of strain KKA101 grown in conditioned
media containing no 1H scFv, lane 2.
Andersen et al. BMC Biotechnology 2011, 11:126
http://www.biomedcentral.com/1472-6750/11/126
Page 8 of 11strain KKA300 and the DNA sequence verified by
sequencing.
Western Blot
The transformants were grown in MRS with 5 μg/ml ery-
thromycin until an OD600 of 1.0. The cultures were cen-
trifuged at 3,200 × g to separate the pellet from the
supernatant. The supernatant was filter sterilised, pH
adjusted to 7.0, dialysed against 10 mM Tris (pH 8.0) and
concentrated using Amicon Ultra-4 centrifugal filter units
(10 kDa cut off, Millipore, Carrigtwohill, Co. Cork, Ire-
land). The concentrated supernatant was mixed with 2 ×
Laemmli buffer and boiled for 5 minutes (min). The cell
culture pellet was washed twice with PBS, resuspended in
100 μl Laemmli buffer and boiled for 5 min. The cell
extract was centrifuged at 16,000 × g to remove cell debris
and the supernatant containing soluble proteins was kept.
The supernatant and cell extract were run on a 10% SDS-
polyacrylamide gel at 170 volts and the proteins were
transferred onto a nitrocellulose membrane (Hybond-ECL,
GE Healthcare, Little Chalfont, Buckinghamshire, UK).
The membrane was blocked with PBS-T (PBS with 0.05%
(v/v) Tween 20 + 5% (w/v) milk powder) and successively
incubated with mouse anti-E-tag antibodies (1 μg/ml, GE-
Healthcare) and HRP (horse radish peroxidase) labelled
goat anti-mouse antibodies (DAKO A/S, Glostrup Den-
mark). The signal was detected by chemiluminescence
using the ECL Plus™ Western Blotting detection system
(GE Healthcare).
For re-attachment of 1H scFv on lactobacilli, strains
KKA317 and KKA101 were grown in 50 ml MRS with 5
μg/ml erythromycin until OD600 of 1.0. Cultures were
harvested by centrifugation and supernatant filter sterilised
and adjusted to pH 7.2. The conditioned media were re-
inoculated with KKA317 and KKA101 at an OD600 of 0.2
and grown to OD600 of 1.0. Cell pellets were treated as
previously described and run on an 10% SDS-polyacryla-
mide gel and Western blotted.
Enzyme-Linked ImmunoSorbent Assay (ELISA)
96 well microtiter plates (EIR/RIA plate, Costar, Lowell,
M A )w e r ec o a t e dw i t h1 0 0μl rPA (List labs, Campbell,
CA) at 1 μg/ml in PBS overnight (o/n) at 4°C. Plates were
subsequently blocked with 200 μl1 %B S A( i nP B Sc o n -
taining 0.05% Tween 20, PBS-T) for two hours at 4°C.
After washing with PBS-T, dilutions of scFv producing
Lactobacillus culture supernatants were added and the
plates incubated at 4°C o/n. ScFvs purified from E. coli
were used as a positive control for quantification. Plates
were subsequently washed three times and 100 μlm o u s e
anti-E-tag antibody (GE-healthcare) was added (1 μg/ml)
in blocking solution, followed by incubation at room tem-
perature for 2 h. Plates were then washed three times in
PBS-T and incubated with 100 μl AP conjugated rabbit
anti-mouse antibody at 1/1000 (Dako A/S, Glostrup Den-
mark) in blocking solution. Following an additional 1 hour
incubation at room temperature, the plates were washed
twice in PBS-T and once in PBS, resuspended in 100 μlo f
diethanolamine buffer (1M, pH 10.0) containing 1 mg/ml
pNPP (Sigma-Aldrich, St. Louis, MO) and absorbance was
read after 10-30 min at 405 nm in a Varioskan Flash
(Thermo Scientific, Waltham, MA).
Flow cytometry
50 μlo fLactobacillus cultures grown to an OD600 of 1.0
in MRS were harvested by centrifugation (8000 rpm, 1
min) and washed three times in PBS. Bacteria were resus-
pended in 50 μl PBS with 1% BSA (PBS-BSA) and incu-
bated for 30 min on ice sequentially with 30 μl PA coated
beads (Invitrogen), 50 μl anti-E-tag antibody (10 μg/ml)
and 50 μl FITC conjugated anti-mouse immunoglobulins
(diluted 1/100) (Jackson Immunoresearch Laboratories,
West Growe, PA), all diluted in PBS-BSA. Bacteria were
washed with 500 μl PBS between all three incubations.
Samples were resuspended and fixed in 300 μl2 %p a r a f o r -
maldehyde in PBS and analysed using a FACS Calibur
machine (Becton Dickinson, Franklin Lakes, NJ). 1 μmr e d
FluoSpheres
®microspheres (Invitrogen) were incubated
with rPA (List labs) according to manufactors instructions
to generate PA coated fluorescent beads for use in flow
cytometry.
Macrophage toxicity assay to assess neutralisation by
scFvs
Protection by Lactobacillus and E. coli produced scFvs
were analysed by their capacity to protect the J774 MF
cell line from killing by LT [36,37]. Briefly, J774 MF were
added to 96-well, flat-bottom wells (5 × 10
4 MF/well) and
i n c u b a t e da t3 7 ° Ci n5 %C O 2 in air. After 12 hours of
incubation, LT (i.e., 1 μg/ml rPA and 1 μg/ml LF, (List
labs)) pre-mixed with scFvs were added to the cultures
and incubated for an additional 12 hours. Viable MF were
evaluated by colorimetric assay by reading absorption at
562nm after addition of Methylthiazolyldiphenyl-tetrazo-
lium bromide (MTT) (Sigma-Aldrich) [38]. MTT was
used at a concentration of 5 mg/ml, and a volume of 20 μl
(100 μg/well) was added to individual wells.
Purification of scFvs
ScFv was purified from the supernatant of strains KKA308
and KKA317, grown in defined minimal media [39]. The
scFv was isolated on a HiTrap™ anti-E-Tag Column (GE-
healthcare) according to the manufactures instructions.
Eluate was concentrated on Amicon Ultra-4 10K MWCO
spin column (Millipore, Billerica, MA). The concentration
of purified scFv was determined using the Micro BCA™
Protein Assay kit (Pierce, Rockford, IL) with BSA as a
standard.
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recombinant E. coli strain, KKA300, as previously
described [35] with the following modifications. The cul-
ture was grown in 500 ml YT-broth supplemented with
100 mM glucose and 100 μg/ml ampicilin. The periplas-
mic extract dialyzed against PBS was adjusted to 30 mM
imidazole (Sigma Aldrich) and 0.5 M NaCl (pH 7.5). The
adjusted periplasmic extract was immobilised on a 5 ml
HisTrap™ HP Column (GE-healthcare) and washed with
20 bed volumes wash buffer (PBS, 30 mM imidazole,
0.5 M NaCl, pH 7.5) and subsequently eluted with 5 bed
volumes elution buffer (PBS, 0.5 M imidazole, 0.5 M
NaCl, pH 7.5). Eluate was concentrated and buffer
exchanged with PBS on a Amicon Ultra-4 10K MWCO
spin column (Millipore, Billerica, MA) and purified scFv
concentration determined as described above.
In vivo neutralisation
Female C57BL/6 mice, six-seven weeks of age, were
obtained from Jackson Laboratories (Bar Harbor, ME).
Mice were maintained under specific pathogen-free con-
ditions and provided food and water ad libitum. All stu-
dies were performed in accordance with both National
Institutes of Health and Institutional guidelines and
approved by the Ohio State University Institutional Ani-
mal Care and Use Committee (Protocol number
2009A0210).
A dose study of the oral effect of ET was carried out on
groups of mice challenged with 10, 25, 50 and 100 μgo f
ET (equal amount of rPA plus EF (List Labs)) given in
100 μl PBS by gavage. After 16 hours, the toxic effect was
measured as ET induced fluid accumulation in the small
and large intestine. Mice were euthanized with CO2 and
death confirmed by cervical dislocation prior to removal
of small and large intestine. Fluid accumulation was mea-
sured as percent of the weight of the small and large intes-
tine compared to total body weight.
The KKA307, KKA308, KKA317 and L. paracasei
pAF400 [25] strains were grown in MRS to an OD600 of
1.0, harvested by centrifugation and resuspended in cul-
ture supernatant with pH adjusted to 7.0 to give 5 × 10
9
cfu/ml. Nine-twelve weeks old C57BL/6 mice (body
weight 15-20 g) were given 2.5 × 10
9 cfu recombinant Lac-
tobacillus by gavage. Four hours later they were challenged
with a non-lethal dose of 50 μg ET (50 μg rPA plus 50 μg
EF (List Labs)) together with an additional 2.5 × 10
9 cfu
recombinant Lactobacillus by gavage. After 16 hours, the
toxic effect of the ET was measured as fluid accumulation
in the small and large intestine.
Statistical analysis
The relative intestinal weight, in percent of total body
weight of the treated groups, were compared to mice
group receiving ET only, and analysed with the Mann-
Whitney U-test using the GraphPad Prism software.
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